VRTX240705C477500
- 0.40
- +0.35+700.00%
Vertex Pharmaceuticals Newsroom
Vertex's (VRTX.US) new generation small molecule combination therapy has received FDA and EMA approval for market application.
It is reported that the Zhitongcaijing APP learned that Vertex Pharmaceuticals (VRTX.US) announced that the U.S. FDA has accepted its new drug application (NDA) for once-daily vanczaftor/tezacaftor/deutivacaftor triple therapy (Vanza Triple Therapy) for the treatment of cystic fibrosis (CF) patients aged 6 and above. These patients have at least one F508del mutation or another responsive mutation in the CFTR gene. Patients with these mutations respond to Van
FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis
Vertex Pharmaceuticals (VRTX) said Tuesday that the US Food and Drug Administration has accepted its new-drug application for the combination therapy of vanzacaftor, tezacaftor, and deutivacaftor to t
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy
By Colin Kellaher Vertex Pharmaceuticals has won Food and Drug Administration priority review for its application seeking approval of a triple combination therapy for the genetic lung disease cystic
Express News | Vertex Pharmaceuticals Inc: EU Marketing Authorization Application (Maa) Submission Validated by EMA
Express News | Vertex Pharmaceuticals Inc: Vanza Triple Granted Priority Review With Prescription Drug User Fee Act (Pdufa) Target Action Date of January 2, 2025
Express News | Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis
Vertex to Announce Second Quarter 2024 Financial Results on August 1
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.43% on an annualized basis producing an average annual return of 19.36%.
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): EVP and CMO Carmen Bozic Sells 2,280 Shares
On June 26, 2024, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 2,280 shares of the company.
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$1.08 Million in Common Stock
$Vertex Pharmaceuticals(VRTX.US)$ Officer Bozic Carmen sold 2,280 shares of common stock on Jun 26, 2024 at an average price of $471.72 for a total value of $1.08 million.Source: Announcement What is
Wells Fargo Updated Its Signature Picks, With Vertex Pharma and AvalonBay as Adds
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic
Redburn Atlantic Initiates Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $545
Redburn Atlantic analyst Steve Chesney initiates coverage on $Vertex Pharmaceuticals(VRTX.US)$ with a buy rating, and sets the target price at $545.According to TipRanks data, the analyst has a succes
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target
Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $577, according to analysts polled by Capital IQ.
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals's (NYSE:VRTX) short percent of float has risen 15.75% since its last report.
Gain Rotation Out of Semis Is Feeding Into Other Parts of the Market - Argus
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 1.08 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 26, $Vertex Pharmaceuticals(VRTX.US)$ Officer Bozic Carmen intends to sell 2,280 shares of its common stock on Jun 26, with a total market value of approximately $1.08 mill